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Abstract: Upregulation of carbonic anhydrase IX (CAIX) was found to be associated with unfavorable
prognosis and resistance to treatment in a broad spectrum of malignancies, recently also in classical
Hodgkin’s lymphoma (cHL). As demonstrated, variable CAIX expression in a significant number
of cHL cases was associated with poor treatment response. The current study focused on the
quantification CAIX immunopositivity and its relative expression compared to the total CD30+
neoplastic pool using digital image analysis. One hundred and one lymph node samples featuring
cHL histology were analyzed for both CD30 and CAIX by immunohistochemistry. Whole histological
slides were scanned and immunopositivity was determined as the histoscore (H-score) using
the DensitoQuant software module (3DHistech Kft., Budapest, Hungary). CAIX positivity was
observed in the HRS-cells of 56/101 cases (55.44%) and frequently observed in the proximity of
necrotic foci. CAIX H-scores were highly variable (range: 2.16–90.36, mean 18.7 ± 18.8). Individual
CAIX values were independent of the much higher CD30 values (range 3.46–151.3, mean 52.37 ± 30.74).
The CAIX/CD30 index proved to be the highest in the aggressive lymphocyte-depleted (LD)
subtype (CAIX/CD30: 0.876). The CAIX expression and the CAIX/CD30 relative index can be
precisely determined by image analysis, and values reflect the extent of a tumor mass undergoing
hypoxic-stress-related adaptation in the most aggressive forms of cHL.
Keywords: classical Hodgkin’s lymphoma; digital image analysis; virtual slide; hypoxia; necrosis;
CAIX; CD30
1. Introduction
Classical Hodgkin’s lymphoma (cHL) is a unique B-cell derived lymphatic malignancy featured
by characteristic morphology. As a key feature, cHL presents with highly enlarged atypical neoplastic
cells (Hodgkin–Sternberg–Reed cells, HRS cells) surrounded by a rich reactive cell infiltrate, consisted
of lymphocytes, plasma cells, histiocytes, and stromal elements. Moreover, the infiltrate may be
accompanied by necrotic foci. According to the WHO 2016 classification, cHL can be further subdivided
into four histological subgroups: Nodular sclerosis (NS), mixed cellularity (MC), lymphocyte rich (LR),
and lymphocyte depleted (LD) cHL [1,2]. NS is the most frequent subtype of cHL accounting
for approximately 80% of the cases and characterized by fibrosis and the nodular arrangement of
the neoplastic HRS-cell component. MC is the second most frequent type composed of a mixture
of neoplastic cell clusters and a high variety of activated inflammatory cells. In contrast, the LR
subtype is dominated by monotonous fields of small lymphocytes and only limited numbers of HRS
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cells. LD histology is associated with the worst clinical prognosis. The paucity of the lymphoid
component and the abundance of the HRS cells in a solid tumor-like fashion is typically observed here.
HRS-cells show an aberrant immunophenotype highlighted by massive CD30 expression in virtually
all cases and further, the loss of leukocyte common antigen (CD45RA) and the B-cell marker CD20 [3].
Overexpression of CD30 in the HRS-cells is highly characteristic in cHL and is one of the key diagnostic
features [4,5]. CD30, a 120 kD membrane-associated glycoprotein is a member of the tumor necrosis
receptor family and has a crucial role in antiapoptotic signaling and in cytokine expression [5–7].
Hypoxia may frequently develop in progressive solid tumors both in a transient or a long term
fashion. Hypoxia-inducible transcriptional Factor 1α (HIF1α) is a major regulator of the functional
and metabolic adaptation through the activation of multiple signaling pathways [8,9]. Carbonic
anhydrases and especially carbonic anhydrase IX and XII (CAIX and CAXII) have a pivotal role in
the adaptation to hypoxia-driven acidosis, therefore, they are also considered as endogenous hypoxia
markers. The effective enzymatic neutralization of the intracellular acidosis due to increased lactate
production consequently contributes to the decrease of the extracellular pH [10]. CAIX upregulation
was found to be associated with cellular quiescence and extended survival and was reported to be
related with unfavorable outcome and disease progression in e.g., breast and stomach cancer [11–14].
In our previous study, we examined the expression of CAIX in HRS-cells of cHL samples using
immunohistochemistry and concluded that high CAIX expression influences disease outcome and
may play a special role in the short term failure of the applied chemotherapy [15]. However, due
to the variable number and uneven distribution of neoplastic HRS cells in the background of the
non-neoplastic inflammatory cells, the exact quantification of CAIX immunopositivity was not enabled
by conventional light microscopy. Therefore, we decided to perform a quantitative evaluation of HRS
cells using digitalized slides enabling objective selection and segmentation of specific immunolabeling
in the relevant tissue areas. Whole slide digital analysis (WSD) provides the visual control of the
neoplastic cells and their microenvironment for the same time, which is especially challenging in
cHL [16,17]. Literature is available on image analysis approaches in a wide range of tumors, however,
the number of studies on cHL is still limited [18–20]. According to our current approach, CD30 IHC
labeling was applied as the most accurate way to represent the total amount of HRS cells which
can be used as a reference for further functional studies. In the present work, the expression of
CD30 and CAIX was measured in parallel within digital slides to establish the relation between the
malignant cell burden (represented by CD30 positive HRS cells) and adaptive changes highlighted by
CAIX-related immunolabeling.
2. Results
2.1. CD30 and CAIX Expression in Hodgkin’s Lymphoma
cHL samples included all showed a robust and clear CD30 immunostaining which selectively
labeled the full spectrum of HRS cells as expected (Figure 1A). CAIX immunohistochemistry provided
a specific but highly variable reaction on a subset of large atypical cells with HRS morphology. Virtually
no other cell types were found to be positive (Figure 1B). The dominantly strong membrane and weak
cytoplasmic immunostaining allowed a simple differentiation between positive and negative HRS cells
in the microscope with only little limitation. Out of the 101 samples analyzed, 56 cases (55.44%) were
considered as positive for CAIX, the residual 45 cases (44.5%) showed no clear sign of CAIX-related
immunolabeling. Within the CAIX-positive samples, areas with labeled and unlabeled HRS cells were
also seen, sometimes with clear cluster formation. Moreover, significant intercellular heterogeneity was
also observed. As expected, in cases with morphologically manifest tumor necrosis, the perinecrotic
areas were typically enriched. Necrotic foci were usually classically surrounded by sheaths of CAIX+
neoplastic cells representing the adaptation zone (Figure 1B).
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Figure 1. CD30 expression (A) representing Hodgkin–Sternberg–Reed (HRS) cells and partially 
carbonic anhydrase IX (CAIX) positivity (B) demonstrating hypoxia-related adaptation in a subset of 
the neoplastic compartment surrounded by reactive cell masses characteristic for classical Hodgkin’s 
lymphoma (cHL). Variable levels of membrane/cytoplasmic CAIX expression could be observed in 
the neoplastic HRS cells while the non-neoplastic background remained virtually negative. Samples 
with necrosis showed intense CAIX expression in the perinecrotic area (arrows). Asterix indicates the 
center of the necrotic area. Scale bar = 100 μm. 
While necrosis was found only in 26.7% (27/101) of the evaluated samples, 85.0% of these 
samples presented with CAIX-positive neoplastic cells (Table 1). 
The total study cohort of 101 samples covered the histological spectrum of cHL and consisted of 
70 NS, 20 MC, 7 LR, and 4 LD cases presenting with different CAIX expression rates (Table 1). Of 
note, cases with LD and NS subtypes were highly positive for CAIX with rates of 4/4 (100%) and 46/70 
(65.71%), respectively. In contrast, MC and LR subtypes were only rarely positive (4/20, 20.0% and 
2/7, 28.57%). 
  
Figure 1. CD30 expression (A) representing Hodgkin–Sternberg–Reed (HRS) cells and partially
carbonic anhydrase IX (CAIX) positivity (B) demonstrating hypoxia-related adaptation in a subset of
the neoplastic compartment surrounded by reactive cell masses characteristic for classical Hodgkin’s
lymphoma (cHL). Variable levels of membrane/cytoplasmic CAIX expression could be observed in the
neoplastic HRS cells while the non-neoplastic background remained virtually negative. Samples with
necrosis showed intense CAIX expression in the perinecrotic area (arrows). Asterix indicates the center
of the necrotic area. Scale bar = 100 µm.
While necrosis was found only in 26.7% (27/101) of the evaluated samples, 85.0% of these samples
presented with CAIX-positive neoplastic cells (Table 1).
The total study cohort of 101 samples covered the histological spectrum of cHL and consisted of
70 NS, 20 MC, 7 LR, and 4 LD cases presenting with different CAIX expression rates (Table 1). Of note,
cases with LD and NS subtypes were highly positive for CAIX with rates of 4/4 (100%) and 46/70
(65.71%), respectively. In contrast, MC and LR subtypes were only rarely positive (4/20, 20.0% and
2/7, 28.57%).
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Table 1. Characteristics of the 101 cHL cases evaluated for CAIX and CD30 immunopositivity by both
light microscopy and digital image analysis (H-score). N: number, CAIX: Carbonic anhydrase, cHL:
classical Hodgkin’s lymphoma, NS: Nodular sclerosis, MC: Mixed cellularity, LR: Lymphocyte rich, LD:
Lymphocyte depleted.
N %
CAIX positivity
Total 56/101 55.44
NS 46/70 65.7
MC 4/20 20.0
LR 2/7 28.6
LD 4/4 100.0
Necrosis
CAIX+ 23/27 85.0
CAIX- 4/27 14.8
Female
CAIX+ 30/48 62.5
CAIX- 18/48 37.5
Male
CAIX+ 26/53 49.0
CAIX- 27/53 50.9
B-symptoms
CAIX+ 29/48 60.4
CAIX- 19/48 39.5
Age
Mean 36.66
<60 years 87/101 86.1
>60 years 14/101 13.8
2.2. Measurement of CAIX and CD30 Expression on Digital Slides
Staining intensity measurements were done following the positive selection for both CD30 and
CAIX in all suitable areas using the DensitoQuant module of the QuantCenter 2.0 (Figure 2). H-scores
were determined by measuring the total pixel counts for each of the three intensity levels (high,
medium, and weak staining intensities). A cut-off level of immunopositivity (H-score> 1.0) was set
following the measurement and careful evaluation of immunohistochemistry (IHC)-negative non-cHL
lymph node control samples treated and stained the same way. The utility of this cut-off value proved
to be valid as it was never reached in CAIX-negative cHL slides.
Image analysis measurement of CD30 resulted in highly variable values (H-scores between
3.38 and 151.33, mean: 45.7 ± 29.3). CAIX H-score values were generally very low (between 0.01
and 0.99, mean 0.37 ± 0.29) in the negative samples (n = 45) and proved to be significantly higher in the
positive samples (H-score range: 2.16–90.36, mean 18.7 ± 18.8) (n = 56) determined by conventional
light microscopy.
To explore the relation between the total neoplastic CD30+ cell mass and the occurrence of CAIX+
cell clusters we first compared the total amount of CD30-staining between the CAIX-negative and the
CAIX-positive slides. Samples lacking CAIX-positivity presented with a significantly lower CD30-score
(H-score range: 3.38–118.2, mean 37.38 ± 25.34) compared to CAIX-positives (CD30 H-score range:
3.46–151.33, mean 52.37 ± 30.74). Accordingly, the CD30+ mass proved to be significantly increased in
association with the occurrence of CAIX+ fraction (Mann–Whitney U-test, p = 0.008) (Figure 3, Table 2).
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Figure 2. DensitoQuant digital image analysis of CD30 and CAIX-immunolabeling in CAIX positive 
(A) and negative (B) classical Hodgkin’s lymphoma. Immunopositivity of large atypical HRS cells 
(left) is highlighted as pseudocolored pixels (yellow/orange/red) following digital segmentation 
(right). Number and intensity of positive pixels were expressed as individual H-score for each sample. 
Scale bar = 100 μm. 
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mean 0.37 ± 0.29) in the negative samples (n = 45) and proved to be significantly higher in the positive 
samples (H-score range: 2.16–90.36, mean 18.7 ± 18.8) (n = 56) determined by conventional light 
microscopy. 
Figure 2. DensitoQuant digital image analysis of CD30 and CAIX-i munolabeling in CAIX positive
(A) and negative (B) classical Hodgkin’s lymphoma. I munopositivity of large atypical HRS cells
(left) is highlighted as pseudocolored pixels (yellow/orange/red) following digital segmentation (right).
Number and intensity of positive pixels were expressed as individual H-score for each sample. Scale
bar = 100 µm.
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CAIX immunopositivity proved to be highly variable, but CAIX H-score values (range: 2.16–
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Figure 3. Distribution and mean values of CD30 and CAIX-related H-scores determined by image
analysis. The figure demonstrates the individual H-score values determined for the CAIX-negative
(n = 45) and CAIX-positive (n = 56) groups defined by light microscopy. As negative control CD30-
and CAIX-double ative onclonal lymphoproliferations were measured (n = 8). The CD30
H-scores representing the total HRS cell burden proved to be higher in CAIX-positive compared to the
CAIX-negative samples according to the Mann–Whitney test (p-value = 0.008, statistically significant).
Table 2. H-score based relative CAIX-expression (CAIX/CD30) according to the different histological
subtypes of cHL (* only two samples, low cell numbers).
n CD30 Mean CAIXMean CAIX/CD30 Ratio
All cases 101/101 45.7 ± 29.3 10.54 ± 16.65 0.23 ± 0.57
CAIX- total 45/101 37.38 ± 25.34 0.37 ± 0.29 0.01 ± 0.01
CAIX+ total 56/101 52.37 ± 30.74 18.70 ± 18.88 0.35 ± 0.61
NS 46/70 49.86 ± 7.49 17.46 ± 15.8 0.35 ± 0.57
MC 4/20 80.46 ± 52.23 11.13 ± 10.62 0.13 ± 0.20
LR * 2/7 9.114 ± 9.325 7.64 ± 5.63 0.83 ± 0.60
LD 4/4 63.16 ± 32.9 55.3 ± 36.8 0.87 ± 1.12
2.3. Relation of CAIX to CD30 in cHL
CAIX immunopositivity proved to be highly variable, but CAIX H-score values (range: 2.16–90.4,
mean 18.7± 18.8) appeared generally lower than CD30 H-scores (range: 3.46–151.33, mean 52.37 ± 30.74)
suggesting the partial upregulation of the enzyme according to the functional diversity of HRS cell
subpopulation (Figure 3).
While the CD30+ burden was generally increased in the CAIX+ compared to the CAIX− samples,
there was no further positive correlation between the amount of CD30+ mass and the extent of CAIX+
cells within individual CAIX+ cases (p-value = 0.475, Spearman rs: −0.008) (Figure 4).
The relation between individual CAIX and CD30 H-score values could be also established on
a case-by-case basis. CAIX H-scores exceeding CD30 values were found in altogether 6/56 (10.7%)
samples and these were generally associated either with low HRS-counts or with unexpected low
CD30-staining intensities.
Independent of CAIX expression, the overall HRS cell burden reflected by the CD30 H-score
proved to be the highest in the LD subtype (n = 4, range: 24.29–109.95, mean: 63.1 ± 32.9). A wide range
of CD30 positivity was observed in the NS (n = 70, range: 2.16–128.3, mean: 46.85 ± 27.5) and in the
MC subtypes (n = 20, range: 3.38–151.3, mean: 45.65 ± 35.2) showing similar distribution. The lowest
CD30 H-scores were detected in the LR subtype as expected (n = 7, range: 2.518–28.5, mean: 17.5 ± 8.8).
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Figure 4. The CD30 related H-score representing the HRS cell burden did not correlate with the amount
of CAIX expression in individual CAIX+ cHL samples (p-value = 0.4755, Spearman rs: −0.008).
Figure 5 graphically presents the specific relation of the matched values according to the
histological cHL subgroups. The highest CAIX-levels (mean 55.3 with a maximum value of 90.36) were
demonstrated in the LD hile the lowest (mean 7.64, maximum 9.2) in the LR subtype with significant
variability, a observed in all other histological groups.
Int. J. Mol. Sci. 2019, 20, x 8 of 12 
 
Figure 5. CAIX and CD30 H-scores measured in serial sections of CAIX-positive cHL (n = 56) 
according to the histological subtypes. CAIX H-score exceeded CD30 in six samples which was 
associated with low HRS-counts or low CD30 staining intensity. 
To better characterize the intratumor variability, the relative positivity rate, expressed by the 
CAIX/CD30 ratio was also calculated for all cHL subtypes. The mean ratio was 0.23 ± 0.57 for all 
evaluated samples and 0.35 ± 0.61 for CAIX-positive samples. Significant differences among the 
histological variants could be demonstrated (Table 2.). The LD subtype showed the highest relative 
immunopositivity for CAIX as the CAIX/CD30 index reached 0.87. While in NS cases the CAIX-
relative index was 0.35, the MC subtype presented with modest relative positivity (0.13). Although 
the relative CAIX/CD30 index remained high (0.83) in the LR subtype, the low number of cases and 
rare positive events within the samples measured did not allow further statistical considerations. 
3. Discussion 
Hypoxia-related adaptation and focal necrosis are both important hallmarks of malignant 
progression [8,21–23]. Although ischemia and tumor necrosis in histological conditions is considered 
as a progressive sign associated with massive proliferation activity in selected cancer types (e.g., 
glioblastoma), adaptive mechanisms to hypoxia are rarely considered and the clinical utility of 
hypoxia-related signs, such as CAIX expression, is still underrated. Unlike the most common 
malignancies, there is only a limited number of studies about hypoxia-associated changes in 
lymphatic neoplasias, including cHL [15]. cHL belongs to the relatively mild forms of lymphomas 
with overall survival rates of above 80% [1,2]. The remaining cases, on the other hand, may show 
rapid progression, relapse and aggressive transformation with high cell proliferation rates and 
frequent tissue necrosis. While the clinical impact of necrosis could not be established so far, in a 
recent work we presented a statistically significant correlation between CAIX expression determined 
by immunohistochemistry and the unfavorable response to first-line therapy in cHL. We also stated 
that the exact quantification of the CAIX+ compartment is challenging as CAIX appears regionally in 
a highly variable and heterogeneous fashion. 
In the present study, we aimed to determine the expression levels of CAIX related to the CD30-
expressing neoplastic cell mass present in the sample. CD30 immunostaining is one of the basic 
markers which presents the full spectrum of transformed HRS cells characteristic for cHL in 
Figure 5. CAIX and CD30 H-scores measured in serial sections of CAIX-positive cHL (n = 56) according
to the histological subtypes. CAIX H-score exceeded CD30 in six samples which was associated with
low HRS-counts or low CD30 staining intensity.
To better characterize the intratumor variability, the relative positivity rate, expressed by the
CAIX/CD30 ratio was also calculated for all cHL subtypes. The mean ratio was 0.23 ± 0.57 for all
evaluated samples and 0.35 ± 0.61 for CAIX-positive samples. Significant differences among the
histological variants could be demonstrated (Table 2). The LD subtype showed the highest relative
immunopositivity for CAIX as the CAIX/CD30 index reached 0.87. While in NS cases the CAIX-relative
index was 0.35, the M subtyp p sente wit modest relative positivity (0.13). Although the relative
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CAIX/CD30 index remained high (0.83) in the LR subtype, the low number of cases and rare positive
events within the samples measured did not allow further statistical considerations.
3. Discussion
Hypoxia-related adaptation and focal necrosis are both important hallmarks of malignant
progression [8,21–23]. Although ischemia and tumor necrosis in histological conditions is considered
as a progressive sign associated with massive proliferation activity in selected cancer types (e.g.,
glioblastoma), adaptive mechanisms to hypoxia are rarely considered and the clinical utility of
hypoxia-related signs, such as CAIX expression, is still underrated. Unlike the most common
malignancies, there is only a limited number of studies about hypoxia-associated changes in lymphatic
neoplasias, including cHL [15]. cHL belongs to the relatively mild forms of lymphomas with overall
survival rates of above 80% [1,2]. The remaining cases, on the other hand, may show rapid progression,
relapse and aggressive transformation with high cell proliferation rates and frequent tissue necrosis.
While the clinical impact of necrosis could not be established so far, in a recent work we presented a
statistically significant correlation between CAIX expression determined by immunohistochemistry
and the unfavorable response to first-line therapy in cHL. We also stated that the exact quantification
of the CAIX+ compartment is challenging as CAIX appears regionally in a highly variable and
heterogeneous fashion.
In the present study, we aimed to determine the expression levels of CAIX related to the
CD30-expressing neoplastic cell mass present in the sample. CD30 immunostaining is one of the
basic markers which presents the full spectrum of transformed HRS cells characteristic for cHL in
histological sections. Despite significant intratumor variability, the CD30 staining proved to be a
robust and useful approach to identify and quantify the malignant cell compartment. In order to
standardize the immunoscoring, we used the DensitoQuant digital analysis tool (3DHistech, Budapest,
Hungary) following digital slide scanning. Pixel-based measurements enabled the exact quantification
of CD30-related immunopositivity which could be expressed as H-scores for each sample. Virtually
CD30-negative lymph node sections enabled to determine the background reaction which was negligible
in these measurements. According to this setting, the CD30 values, measured by digital image analysis
represented the neoplastic cell burden within the individual sections. This approach is in line with
the limited amount of image analysis approaches which examined Hodgkin’s lymphomas on a
slide-based digital platform [19,20,24]. As next, CAIX-related immunopositivity could be determined
and individual H-scores were generated using an almost identical setup. During these measurements,
CAIX was not detected in lymphatic changes other than cHL and results regarding positive staining
were in accurate agreement with those of the conventional microscopy.
The presented method enabled the precise measurement and comparison of the IHC reaction for
both CD30 and CAIX obtained in clinical samples. According to our data, CD30-related H-scores were
generally higher than the CAIX H-scores with only a few exceptions. This was explained by unusual
weak CD30 staining intensities of unknown nature. As a major limitation of any of the IHC methods,
we had to consider the biological variability of patient samples provided for analysis.
Most importantly, more than half of the evaluated samples (56/101, 55.44%) presented with
CAIX-expression, which seemed to be strictly related to the HRS cells. CAIX-positivity separated a
subfraction of the total CD30+ HRS cell mass strongly suggesting that CAIX expression was not an
integral feature of the transformed cells. Moreover, the CAIX staining was frequently associated with
necrotic tissue foci further supporting the functional role of the enzyme in adaptation to hypoxia.
Interestingly, we found a significant difference (Mann–Whitney analysis, p < 0.0001) in the CD30+
tumor-cell burden between the CAIX+ and CAIX− cHL group (Figure 3). This allows the interpretation
that CAIX upregulation occurs in the progressive, tumorous forms of cHL and that it is associated with
the survival advantage of HRS-cells. However, in a further evaluation CAIX-scores did not follow the
increase of CD30 (CAIX+ samples) and no relevant positive correlation was proven (Figure 4).
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CAIX-expression could also be determined in a relative fashion for the first time as matched
H-scores for the CD30-positive malignant cell mass were provided. In general, only a minor fraction
of the HRS-cells presented with CAIX-reaction (mean: 0.35) but this could be further differentiated
according to the histological lymphoma subtype. The most unfavorable clinical prognostic group
(LD) provided the highest relative CAIX-expression (mean 0.87) as expected. The most frequent
intermediate group (NS) presented a significantly lower value (mean 0.35), and the mildest form (MC)
of the disease showed moderate relative H-score ratios (mean 0.13) (Table 2). The lymphocyte-rich
subtype could not be exactly considered due to the low case number (n = 2) and the very low frequency
of the HRS cells (H-score < 10) providing unsatisfactory data for statistical evaluation.
The general clinical interest for biological variables and functional differences within the otherwise
ordinary-appearing malignant proliferations is increasing. The current study focused on the possibilities
and challenges of the digital analysis to determine adaptive changes of an unselected group of malignant
lymphoproliferation. Although our approach in the current phase is exploratory, we could measure
major differences in routine pathological samples in relation to histological features and the tumor
cell mass. This used to be a particularly challenging issue in Hodgkin’s lymphoma as CD30+
malignant B-cells (termed as HRS cells) are provided in a scattered fashion embedded in a rich
reactive/inflammatory lymphatic environment. As stated, CAIX overexpression was a feature of the
malignant cell compartment while the accompanying inflammatory and stromal elements remained
virtually negative. Although there was a close relation of CAIX-expression with hypoxic necrosis
in the aggressive histological variants, obvious signs of necrosis were present only about half of the
CAIX+ cases (27/56, 48.21%). CAIX in cHL, therefore, most probably occurs in a dynamic fashion as an
adaptive feature induced by hypoxic stress. The upregulation of the enzyme suggests the activation of
protective mechanisms in metabolically challenged atypical HRS cells. This might be sorely essential
as this enlarged neoplastic cell type demands basically different O2 and energy supply exceeding that
of the non-neoplastic microenvironment.
In summary, the results show that the CAIX-positive cells compose a subfraction of the
CD30-positive cells, and indicate a significant functional heterogeneity within the malignant clone.
As CAIX-related cancer cell adaptation potentially contributes to an aggressive and resistant phenotype,
analyses of this type open the way for alternative therapeutic considerations.
4. Materials and Methods
4.1. Patients and Specimens
We identified 101 lymph node samples diagnosed with cHL between 1999 and 2018 which were
suitable for the analysis. Only samples from the time of the initial diagnosis were used. Core needle
biopsies were avoided in this study. Histological diagnosis of cHL was given according to 2016
WHO classification.
The archived tissue samples and basic clinical data derived from the pathology departments of the
University of Debrecen in Debrecen, Hungary, and the Jósa András Teaching Hospital, Nyíregyháza,
Hungary. Ethical approval for this study was obtained from the Local Regional Ethics Board
(60355-2016/EKU).
4.2. Immunohistochemistry
Representative lymph node biopsy samples were selected to include typical neoplastic cells.
Immunohistochemistry was done as usual on serial sections using the antibody clone Ber-H2
(Dako-Agilent, Glostrup, Danemark) for CD30 and the rabbit polyclonal antibody clone NB100-417
(Novus Biologicals, Littleton, CO; final dilution 1:2000) for CAIX. Visualization was done by the
diaminobenzidene)(DAB)chromogen using the Bond Max automated system (Leica, Germany).
The result of the IHC reaction was carefully evaluated by light microscopy. To avoid potential
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false positivity, samples with critically low numbers of positive events (less than 10 nucleated
immunopositive cells) were excluded.
4.3. Digital Image Analysis and IHC Scoring
The IHC stained slides were digitalized with the Pannoramic MIDI Scanner (3DHistech Ltd.,
Budapest, Hungary) and the scanned virtual slides were further analyzed. The area of the measurement
was defined for each lymph node section using the CaseViewer slide management software (3DHistech
Ltd., Budapest, Hungary). The size and shape of the annotation was highly individual depending on
the characteristics of the biopsy sample. Irrelevant areas, such as artifacts, glue and stain residues,
air bubbles, tissue folds, etc., were excluded digitally.
As next, the QuantCenter Software 2.0 (3DHistech Ltd., Budapest, Hungary) was applied in order
to identify and score CD30 and CAIX positive cells. This allowed determining individual IHC values
and the CAIX/CD30 relative index representing the whole sample. The DenstioQuant algorithm of
QuantCenter is a stain-intensity measurement module enabling a user-controlled whole slide analysis
on a pixel basis. As an initial step, the IHC signal was controlled and manually optimized to get
reliable monochrome intensity values. Next, pixel intensity levels of the positive reaction were scaled
and displayed in three levels: Weak (yellow), moderate (orange), and strong (red). The background
of negative cells was represented by the blue-stained nuclei and unstained pixels in white color.
The module automatically calculated histoscores (H-score) using individual pixel intensity levels and
the total area of pixels. Ratios for negative, weak, moderate, and strong positives, as well as background
pixels were generated. The H-score representing specific immunolabeling for each slide was used for
further evaluation.
4.4. Statistical Analysis
Associations between paired samples were calculated by nonparametric Wilcoxon paired t-test and
for group-based comparisons, the Mann–Whitney U-test was applied. Nonparametric Kruskal–Wallis
analysis and Spearman’s nonparametric correlation was performed to calculate differences between
CAIX and CD30 values in the matched sample sets using the Graph Pad Prism 7 (GraphPad Software,
La Jolla, CA, USA). Statistical significance was set at p-values was less than 0.05.
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Abbreviations
CAIX Carbonic anhydrase IX
cHL Classical Hodgkin’s lymphoma
HIF1α Hypoxia Inducible transcriptional Factor-1α
HL Hodgkin lymphoma
HRS Hodgkin–Sternberg–Reed cells
IHC Immunohistochemistry
LD Lymphocyte depleted
LR Lymphocyte rich
MC Mixed cellularity
NS Nodular sclerosis
WSD Whole slide digital analysis
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